切换到内部网   |  返回旧版

陈侃

发表于:2020-03-30  浏览人数:



      

别:女

出生年月:1977年6月

称:副教授            

组:细胞生物学学科组

室: 6-309

电子邮件:chenkan@zstu.edu.cn

微信二维码:




主要学习工作经历

1. 1994.09-1999.07 安大学医学院,临床医学系,医学学士

2. 1999.07-2002.08 陕西省汉中市中心医院,住院医师

3. 2002.09-2005.07 西安交通大学医学院,病理学与病理生理学,医学硕士

4. 2005.07-2013.07 浙江理工大学,生命科学学院,讲师

5. 2013.07-2016.09 荷兰鹿特丹伊拉兹马斯大学,医学中心,肝肠胃病,医学博士

6. 2016.09-今 浙江理工大学,生命科学与医药学院,副教授

主要研究方向

1. 慢性肝病(包括非酒精性脂肪肝、脂肪性肝炎、肝癌)的预防与治疗;

2. 肝癌的免疫治疗及其相关研究。

获奖与荣誉

1. 2018年全国高校微课教学比赛一等奖;

2. 2018年浙江理工大学教书育人先进个人;

3. 2018年浙江理工大学“百篇优秀毕业论文”指导教师;

4. 2018年浙江理工大学生命科学与医药学院教学先进个人;

5. 2016年获第51届欧洲肝病年会“青年科学家”称号(西板牙,巴塞罗拉);

6. 2014年浙江理工大学优秀寝室成长导师;

7. 2012年浙江理工大学生命科学学院教学比赛,PPT制作一等奖;

8. 2006年浙江理工大学生命科学学院青年教师讲课比赛二等奖;

科研教学项目

一、科研项目

1. 国家自然科学基金面上项目,IMPDH/PPAR信号通路调控肝癌的机制及其靶向干预研究(81972281),2020/01-2023/12,55万,在研,主持

2. 浙江省自然科学基金一般项目,霉酚酸和IMPDH在肝癌进展中的关联效应研究(LY18H160066),2018/01-2020/12,10万,在研,主持

3. 浙江省科技厅分析测试项目,运用流式细胞术快速检测腺病毒滴度(2012F82G2060018),2012/01-2014/01,已结题,主持

4. 浙江省“生物医学工程”重中之重开放基金,肝癌干细胞的分选、鉴定及其生物学特性的研究(SWYX0812),2009/01-2010/12,已结题,主持

5. 浙江省教育厅一般项目,肝癌干细胞的分选、鉴定及其表面抗原的筛选(20060593),2006/07-2008/12,已结题,主持

6. 国家自然科学基金面上项目,纳米磷酸钙携载药物与肿瘤类器官的相互作用(51672250),2017/01-2020/1262万,在研,3/9

7. 国家自然科学基金面上项目,AnnexinA1调控Notch1/Smad2/p15信号轴促进急性髓系白血病细胞增殖的机制研究(81770176),2018/01-2021/1266万,在研,3/10

8. 浙江省自然科学基金重点项目,癌症靶向双基因-病毒治疗策略的设计及其抗癌效果的实验研究(LZ13H160004),2013/01-2016/12,已结题,3/7

9. 浙江省科技厅平台项目,浙江-毛里求斯(浙理)生物医用材料与组织工程联合研究中心,2019/03-2023/07200万,在研,5/65

二、教改项目

1.《免疫学》线上精品课程建设,2019,校级,在研,主持;

2.《免疫学》浙江省生物学重中之重学科本科教学精品网络课程建设项目,2013,已结题,主持;

3. 基于项目驱动教学法的免疫学课堂教学模式探索,2012,校级课堂教学改革项目,已结题,主持;

4.《免疫学》教学内容与教学模式的实践与探索,2011,校级教改一般项目,已结题,主持

5. 开放性、设计性生物技术综合实验教学体系的建立,2012,校级实验教学改革和实验课程建设项目,已结题,主持

专著论文

1. X Jia, Y Zheng, Y Guo, K Chen*, Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways. Mol Genet Genomic Med. 2019, 7(5):e613. (IF2018=2.448)

2. K Chen, J Ma, X Jia, W Ai, Z Ma, Q Pan*. Advancing the understanding of NAFLD to hepatocellular carcinoma development: from experimental models to humans. BBA reviews on cancer. 2019 Jan, 1871(1):117-125. (IF2018=6.887)

3. K Chen, J Sheng, B Ma, W Cao, P Y Hernanda, J Liu, P P. C. Boor, S. W. Tjon, K Felczak, D Sprengers, K W. Pankiewicz, H J. Metselaar, Z Ma, J Kwekkeboom, M P. Peppelenbosch, Q Pan*. Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients. Transplantation. 2019 May, 103(5):929-937. (IF2018=4.743)

4. K Chen, B Ma,  MP Peppelenbosch, Q Pan*. Cytoplasmic rods and rings in mycophenolic acid treatment. Liver Int. Letter, 2017, 37(11):1742-1743. (IF2018=5.542)

5. K Chen, K Sideras, B Ma, W Cao, L J van de Laan, D Sprengers, R Smits, H J Metselaar, J Kwekkeboom, M P Peppelenbosch, Q Pan*. Nuclear localization of IMPDH2, the primary target of mycophenolic acid, constrains hepatocellular carcinoma. J Hepatology, supplement, 2016, 64(20): S567. (IF2018=18.946)

6. K Chen, W Cao, J Li, D Sprengers, P Y. Hernanda, X Kong, Luc J. W. van der Laan, K Man,  J Kwekkeboom, H J. Metselaar, M P. Peppelenbosch, Q Pan*. Differential Sensitivities of Fast- and Slow-cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid. Mol Med. 2016, 21(1):792-802. (IF2018=2.991

7. P Y Hernanda, K Chen (co-first author), A M Das, K Sideras, W Wang, J Li, W Cao, S J A Bots, L L Kodach, R A de Man, J N M Ijzermans, H L A Janssen, A P Stubbs, D Sprengers, M J Bruno, H J Metselaar, T L M ten Hagen, J Kwekkeboom, M P Peppelenbosch, Q Pan*. SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene, 2015, 34(39):5055-5068. (IF2018=6.634)

8. K Chen, K Man, H J Metselaar, H L A Janssen, J Kwekkeboom, D Sprengers, M J Bruno, M P Peppelenbosch, Q Pan*. IMPDH2-targeted constrain of cell growth in hepatocellular carcinoma by mycophenolic acid. J Hepatology, supplement, 2014, 60(1): S88. (IF2018=18.946)

9. K Chen, K Man, H J. Metselaar, H L. A. Janssen, M P. Peppelenbosch, Q Pan*. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transpl. 2014, 20 (3); 261-269. (IF2018=4.159)

10. K Chen, Q Pan, Y Gao, X Yang, S Wang, M P. Pepplenbosch, X Kong*. DMS triggers apoptosis associated with inhibition of SPHK1/NF-κB activation and increase of intracellular Ca2+ concentration in human cancer cells. Int J Mol Med. 2014, 33(1):17-24. (IF2018=2.928)

11. K Chen, X Yang, L Wu, M Yu, X Li, N Li, S Wang, G Li*. Pinellia pedatisecta Agglutinin Targets Drug Resistant K562/ADR Leukemia Cells through Binding with Sarcolemmal Membrane Associated Protein and Enhancing Macrophage Phagocytosis. PLoS ONE. 2013, 8(9); e74363. (IF2018=2.776)

12. B Ma, K Chen, P Liu, M Li, J Liu, K Sideras, D Sprengers, K Biermann,W Wang, JNM IJzermans,W Cao, J Kwekkeboom, MP Peppelenbosch,Q Pan*. Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma. J Mol Med. 2019, 97(1):77-88. (IF2018=4.746)

13.P Liu, W Cao, B Ma, M Li, K Chen, K Sideras, JW Duitman, D Sprengers, TCK Tran, JNM Ijzermans, K Biermann, J Verheij, CA Spek, J Kwekkeboom, Q Pan, MP Peppelenbosch*. Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma. Carcinogenesis. 2019, 40(1):155-163. (IF2018=4.004)

12. W Cao , J Liu , L Wang , M Li , MMA Verstegen , Y Yin , B Ma , K Chen , M Bolkestein , D Sprengers , LJW van der Laan , M Doukas , J Kwekkeboom , R Smits , MP Peppelenbosch , Q Pan*. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Carcinogenesis. 2019, 40(1):145-154. (IF2018=4.004)

13. W Cao, K Chen, M Bolkestein, Y Yin, MMA Verstegen, MJC Bijvelds, W Wang, N Tuysuz, B D Ten, D Sprengers, HJ Metselaar, LJW van der Laan, J Kwekkeboom, R Smits, MP Peppelenbosch, Q Pan*. Dynamics of Proliferative and Quiescent Stem Cells in Liver Homeostasis and Injury. Gastroenterology. 2017,153(4):1133-1147. (IF2018=19.809

14. W Wang, Y Yin, L Xu, J Su, F Huang, Y Wang, PPC Boor, K Chen, W Wang, W Cao, X Zhou, P Liu, LJW van der Laan, J Kwekkeboom, MP Peppelenbosch,Q Pan*. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Sci Signal, 2017,10(476) pii: eaah4248. (IF2018=6.565

15. W Wang, L Xu, P Liu, K Jairam, Y Yin, K Chen, D Sprengers, MP Peppelenbosch, Q Pan, R Smits*. Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling. Neoplasia, 2016, 18(12):711-723.  (IF2018=3.837

16. Y Gao, F Gao, K Chen, ML Tian, DL Zhao*. Sphingosine kinase 1 as an anticancer therapeutic target. DRUG DES DEV AND THER, 2015, 9:3239-3245. (IF2018=3.208

17. Y Wang, X Zhou, Y Debing, K Chen, L JW. Vander Lanna, J Neyts, H L.A. Janssen, He J. Metselaar, M P Peppelenbosch, Q Pan*. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology, 2014, 146(7);1775-83. (IF2018=19.809

18. Y Gao*, K Chen, J Ma, F Gao. Cerium oxide nanoparticles in cancer. Onco Targets Ther, 2014, 7:835-40. IF2018=3.046

19. 陈侃*,潘兰兰,邱梦芸. TFH细胞调控因子研究进展,科学通报,2013, 58(10):901-906.

20. 李晓艳,马晖,潘强,杨新燕,吴丽琴,陈侃*. PTL联合ZD55-TRAIL对肝癌细胞Hep3B生长抑制的研究,中国细胞生物学学报,2013, 35(5):630-636.

21. 田雪君,仰毅,刘菁,陈侃*. 锌指蛋白Miz1磷酸化对其泛素化作用的影响研究,中国生物工程杂志, 2011, 31(8):7-11.

22. 陈侃,田雪君,陈兴国,贾晓渊,李恭楚*,肝癌细胞系中SPCD133+细胞的特性分析,中国细胞生物学学报, 2011, 33(3):244-251.

23. 陈晓黎,何建军,陈侃,来宝长,司履生,王一理*,肿瘤引流淋巴结中免疫活性细胞的分布的原位分析,细胞与分子免疫学杂志,2006, 22(6):748-751.